Management of neonatal aortic arch thrombosis with low-molecular weight heparin: a case series.

Aortic arch thrombosis (AAT) is a potentially life threatening condition in neonates. We report 3 neonates with AAT and complete occlusion of a unilateral internal carotid artery with multiple cerebral infarcts. Multidisciplinary input led to deferral of thrombolytic therapy and surgical thrombectomy owing to the potential risk of hemorrhage within the infarcts.

Current practice perspectives on the management of thrombosis in children with renal insufficiency: the results of a survey of pediatric hematologists in North America.

Background: No guidelines exist for the management of venous thromboembolic events (VTE) in children with renal insufficiency (RI).

Objective: To define current practice patterns of VTE management in children with RI.

Methods: An online multiple choice survey encompassing general questions/clinical scenarios related to thrombosis in RI.

Post-thrombotic syndrome in children: a single center experience.

Background: Development of post-thrombotic syndrome (PTS) is increasingly being recognized as a complication of deep venous thrombosis (DVT) in children.

Objective: To determine the prevalence, clinical characteristics, and predictors of moderate to severe PTS in children.

Methods: A retrospective chart review was performed on those children who were followed in the coagulation clinic for objectively confirmed DVTs from December 2004 to December 2006.

Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy.

Treatment of thrombosis in children with end-stage renal disease (ESRD) is extremely challenging owing to the underlying risk of bleeding. Fondaparinux (Arixtra, Sanofi-Synthélabo), a synthetic pentasaccharide, is contraindicated in patients with compromised renal function as it is excreted via kidneys. We describe a unique case with ESRD and pulmonary embolism who was treated with fondaparinux owing to the toxicity and poor compliance with low-molecular-weight heparin.